EUCTR2005-003413-32-IT进行中（未招募）不适用
A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipients
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 630
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Male or female cardiac recipients 18-70 years of age undergoing primary heart transplantation. ?Patients who have given written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?Calculated creatinine clearance <40 ml/min at screening (MDRD Formula) ?Patients with platelet count <50,000/mm at the evaluation before randomization. ?Patients who are recipients of multiple solid organ transplants. ?Patients who are recipients of ABO incompatible transplants ?Patients with active systemic infection. ?Patients receiving drugs used for non-approved indications in the 30 days prior to study entry. ?Patients receiving induction therapy in non induction center ?Patients not receiving induction therapy in an induction center ?Induction therapy other than Simulect ?Presence of severe hypercholesterolemia (>=350 mg/dL; ≥9 mmol/L) or hypertriglyceridemia (>= 750 mg/dL; >=8.5 mmol/L) before randomization. ?Patients with an absolute neutrophil count of <=61472;1,500/mm3 or white blood cell count of <= 4000/mm3 at baseline before surgery ?Patients with a history of significant coagulopathy or medical condition requiring long term anti-coagulation after transplantation (low dose aspirin treatment is allowed) ?Patients who are HIV-positive or Hepatitis C (PCR+ only) or B surface antigen positive. Laboratory results obtained within 6 months prior to study entry are acceptable. ?Recipients of organs from donors who test positive for Hepatitis B surface antigen or Hepatitis C (PCR+ only) are excluded ?Patients being treated with terfenadine, astemizole, or cisapride ?Patients with any past (within the past 5 years) or present malignancy (other than excised basal cell carcinoma) ?Patients with a known hypersensitivity to drugs of this class. ?Patients with donor greater than 65 years and/or with known donor heart disease at the time of transplant. ?Patients who are treated with drugs strong inducers or inhibitors of cytochrome P450 3A4. ?Cold ischemia time >6 hours.
研究者
相似试验
进行中（未招募）
1 期
A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipientsde novo heart transplantationEUCTR2005-003413-32-DKovartis Pharma Services AG630
进行中（未招募）
不适用
A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipientsde novo heart transplantationMedDRA version: 8.1Level: LLTClassification code 10019314Term: Heart transplantEUCTR2005-003413-32-DEovartis Pharma Services AG630
进行中（未招募）
1 期
A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipients.de novo heart transplantationEUCTR2005-003413-32-BEovartis Pharma Services AG630
进行中（未招募）
不适用
A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipientsEUCTR2005-003413-32-ATovartis Pharma Services AG630
进行中（未招募）
不适用
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0g MMF with standard dose Neoral in de novo heart transplant recipients. -de novo heart transplantationEUCTR2005-003413-32-GBovartis Pharma Services AG590